Rigel Pharma (RIGL) Tops Q4 EPS by 2c, Tops on Revenue
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $47.37 -2.67%
Revenue Growth %: +15.2%
Financial Fact:
Income (loss) from operations: -22.74M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +15.2%
Financial Fact:
Income (loss) from operations: -22.74M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Rigel Pharma (NASDAQ: RIGL) reported Q4 EPS of $0.00, $0.02 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $35.8 million versus the consensus estimate of $34.1 million.
For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Activist investor presses Xerox to review financial services arm - Bloomberg
- BMO Capital Starts Lululemon (LULU) at Underperform
- Braze, Inc. (BRZE) Tops Q2 EPS by 4c; offers guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
